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ype 1 diabetes is characterized by T-cell–medi-
ated destruction of insulin-producing -cells.
The strong association between autoimmune di-
abetes and certain susceptible major histocom-
patibility complex (MHC) class II alleles suggests that
T-cell activation by self-peptides presented via these MHC
class II alleles plays a critical role in the disorder’s
pathogenesis. A diverse repertoire of T-cells is generated
in the thymus, ﬁrst through positive selection on MHC and
self-peptide within the thymic cortex. This process re-
quires adequate peptide presentation through interactions
with MHC and sufﬁcient T-cell receptor (TCR) signaling
through the TCR/MHC/self-peptide complex (Fig. 1). As
such, all T-cells in normal physiology are intrinsically
self-reactive. However, subsequent negative selection of
self-reactive T-cells in the thymic medulla should lead to
clonal deletion for TCRs that recognize self-peptide/MHC
with high afﬁnity. Although some self-reactive, high-avidity
T-cells do escape into peripheral circulation, suboptimal
recognition of MHC/self-peptide by the TCRs may be
required for T-cells to escape tolerance mechanisms. This
idea is supported by experimental observations that the
afﬁnity of TCRs for MHC/self-peptide is generally lower
than that for MHC/foreign peptide and that the interac-
tions of autoreactive TCRs to MHC/self-peptide appear to
be less extensive than to foreign peptide (1,2). In light of
the opposing mechanisms of positive and negative selec-
tion, fundamental questions remain regarding the afﬁnity
of TCR/MHC/self-peptide interactions that give rise to
autoreactive T-cell responses.
There is increasing evidence that insulin may be the
primary autoantigen in the nonobese diabetic (NOD)
mouse model (3). Several studies have emphasized the
insulin B9–23 epitope. This peptide binds to I-A
g7, the
MHC class II molecule in NOD mice, with moderate afﬁnity
(4). Wegmann et al. (5) reported that the majority of CD4
T-cells isolated from pancreatic islets of NOD mice recog-
nized this epitope. Furthermore, an amino acid substitu-
tion within this peptide has also been shown to abrogate
diabetes development in a transgenic mouse line express-
ing this modiﬁed insulin transgene, implying an important
role for this epitope in disease development (6). In hu-
mans, HLA-DR0401-DQ0302 is a major disease susceptibil-
ity haplotype. Considerable effort has been devoted to
identifying the relevant T-cell epitopes in human type 1
diabetes because this knowledge is essential for the study
of autoreactive T-cells. In addition to insulin, multiple
autoantigens have been reported, and many class II
epitopes within each antigen have been identiﬁed (7,8).
These antigenic peptides have generally demonstrated
moderate-to-high afﬁnities when tested for their MHC
binding. Thus, there has been no compelling evidence that
autoreactive T-cells recognize unusually low-afﬁnity pep-
tides. However, there is also no conclusive evidence that
T-cells recognizing these moderate- and high-afﬁnity pep-
tides are the primary pathogenic cells in humans with type
1 diabetes.
In this issue of Diabetes, Levisetti et al. (9) report their
study of the proinsulin 1 47–64 (PI-147–64) epitope in NOD
mice. This peptide is located in the C-peptide region and
has been shown to be naturally processed and presented
(10). In contrast to insulin B9–23, PI47–64 binds to I-A
g7
with a very weak afﬁnity (30-fold lower). In spite of this,
PI-147–64–speciﬁc T-cell lines could be isolated from NOD
mice and expanded in vitro. More notably, these cells
induced diabetes when transferred into NOD.scid recipi-
ent mice with an incidence rate of 50%. These results
demonstrate that high-afﬁnity peptide binding to MHC is
not required to elicit a pathogenic T-cell response, which,
in turn, raises the possibility that low-afﬁnity peptides,
previously ignored in some methodologies, could also play
an important role in type 1 diabetes. It might be expected
that these low-afﬁnity peptides provide a means for escap-
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FIG. 1. The T-cell repertoire is determined by positive and negative
selection. T-cells with sufﬁcient recognition of self-peptide/MHC are
preserved through positive selection (indicated by solid vertical
boundary line); remaining T-cells in the thymic cortex die by neglect
(light-gray shaded region). Positively selected T-cells migrate to the
thymic medulla, where T-cells with excessive recognition of self-
peptide/MHC are deleted through negative selection (indicated by
dashed vertical boundary line). T-cells with intermediate recognition
of self-peptide/MHC survive (checkered region) and migrate to the
periphery.
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1788 DIABETES, VOL. 57, JULY 2008ing central tolerance. This would agree with previous
studies in which the unstable myelin basic protein 1–11/
I-A
u complexes are targets for autoreactive T-cells in the
experimental autoimmune encephalomyelitis mouse
model (11).
The study by Levisetti et al. persuasively demonstrates
that PI-147–64–responsive T-cells can independently cause
autoimmune diabetes. It is also signiﬁcant that these cells
were observed in pre-diabetic mice. The authors assert
that this implies a role for these cells in early pathogenic
processes. However, only 5 of 246 T-cell lines recovered
following two cycles of peptide stimulation were speciﬁc
for this peptide. Therefore, it is possible that T-cells that
target this unstable MHC/peptide complex represent only
a very small percentage of the pathogenic T-cell repertoire
and, consequently, play a minor role in the autoimmune
process underlying type 1 diabetes in this model. It is
interesting, however, given the low afﬁnity of PI47–64 for
I-A
g7, that high-avidity T-cell lines were isolated from
immunized mice (i.e., half-maximal stimulation was
achieved at submicromolar concentrations of peptide). It
has been reported that both the I-A
g7 and DQ0302 mole-
cules form unstable MHC dimers (12,13). In contrast, the
protective DQ0602 allele forms stable dimers (14). Since
peptide binding is essential for stability, weak peptide
MHC complexes (such as I-A
g7 and PI-147–64) could pro-
vide a means for high-avidity T-cells to escape tolerance
mechanisms, particularly for unstable alleles. In fact, it is
plausible that low-afﬁnity peptides may actually select for
higher-avidity T-cells than high-afﬁnity peptides.
Despite the strengths of their study, Levisetti et al. leave
some questions unanswered. For example, they do not
address the signiﬁcance of PI-147–64–speciﬁc T-cells in
spontaneous disease. It is possible that the presentations
of low- and high-afﬁnity self-peptides by MHC play differ-
ent roles at varying times during disease progression. For
example, low-afﬁnity peptides could be prominent early in
the disease process, whereas higher-afﬁnity peptides be-
come more important in later stages. Alternatively, it is
possible that low-afﬁnity peptides become more important
later in the disease process as autoimmune damage and
metabolic stress lead to increased or altered antigen
presentation and costimulation in the inﬂamed tissue. It
may be crucial to assess the role of regulatory T-cells in
controlling PI-147–64–speciﬁc and polyclonal responses. It
is possible that low-afﬁnity peptides such as PI-147–64 are
incapable of generating regulatory T-cells, whereas high-
afﬁnity peptides are involved in activated regulatory T-
cells. Alternatively, low-afﬁnity peptides might generate
T-cells that are less susceptible to regulation. In any case,
it will be wise for future studies to consider the potential
role of low-afﬁnity peptides in the autoimmune process.
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